Search research articles
Contact Us
Filters
Showing results (271-280 of 315) with videos related to
Page
of 32
Sort By:
The New England Journal of Medicine
|
May 30, 2025
Encorafenib, Cetuximab, and mFOLFOX6 in <i>BRAF</i>-Mutated Colorectal Cancer
Elena Elez, Takayuki Yoshino, Lin Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 22, 2008
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
Dan G Blazer, Yoji Kishi, Dipen M Maru, et al.
The Oncologist
|
March 31, 2025
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2
Cathy Eng, Arvind Dasari, Sara Lonardi, et al.
Plos One
|
March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
Amir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2022
Anal Cancer: Emerging Standards in a Rare Disease
Cathy Eng, Kristen K Ciombor, May Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2017
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Christine M Parseghian, Nila U Parikh, Ji Yuan Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 9, 2008
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F Sobrero, Joan Maurel, Louis Fehrenbacher, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 3, 2006
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer
Sunil Krishnan, Nora A Janjan, John M Skibber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct
Sheela Rao, Francesco Sclafani, Cathy Eng, et al.
Cancer
|
November 23, 2017
Physician interpretation of genomic test results and treatment selection
Lauren L Brusco, Chetna Wathoo, Kenna R Mills Shaw, et al.
Page
of 32
Search research articles
Search
Showing results (271-280 of 315) with videos related to
Sort By:
Page
of 32
The New England Journal of Medicine
|
May 30, 2025
Encorafenib, Cetuximab, and mFOLFOX6 in <i>BRAF</i>-Mutated Colorectal Cancer
Elena Elez, Takayuki Yoshino, Lin Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 22, 2008
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
Dan G Blazer, Yoji Kishi, Dipen M Maru, et al.
The Oncologist
|
March 31, 2025
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2
Cathy Eng, Arvind Dasari, Sara Lonardi, et al.
Plos One
|
March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
Amir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2022
Anal Cancer: Emerging Standards in a Rare Disease
Cathy Eng, Kristen K Ciombor, May Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2017
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Christine M Parseghian, Nila U Parikh, Ji Yuan Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 9, 2008
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F Sobrero, Joan Maurel, Louis Fehrenbacher, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 3, 2006
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer
Sunil Krishnan, Nora A Janjan, John M Skibber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct
Sheela Rao, Francesco Sclafani, Cathy Eng, et al.
Cancer
|
November 23, 2017
Physician interpretation of genomic test results and treatment selection
Lauren L Brusco, Chetna Wathoo, Kenna R Mills Shaw, et al.
Page
of 32